Retracted: First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset-Reference-Cited by-同舟云学术

Retracted: First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset

Published:2020-10-16 Issue:12 Volume:111 Page:4480-4489
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci.

Author:

Satouchi Miyako¹^ORCID,Nosaki Kaname²,Takahashi Toshiaki³,Nakagawa Kazuhiko⁴,Aoe Keisuke⁵,Kurata Takayasu⁶,Sekine Akimasa⁷,Horiike Atsushi⁸,Fukuhara Tatsuro⁹,Sugawara Shunichi¹⁰^ORCID,Umemura Shigeki¹¹,Saka Hideo¹²,Okamoto Isamu¹³^ORCID,Yamamoto Nobuyuki¹⁴,Sakai Hiroshi¹⁵,Kishi Kazuma¹⁶,Katakami Nobuyuki¹⁷,Horinouchi Hidehito¹⁸^ORCID,Hida Toyoaki¹⁹^ORCID,Okamoto Hiroaki²⁰,Atagi Shinji²¹,Ohira Tatsuo²²,Han Shi Rong²³,Noguchi Kazuo²³,Ebiana Victoria²⁴,Hotta Katsuyuki²⁵^ORCID

Affiliation:

1. Department of Thoracic Oncology Hyogo Cancer Center Akashi Japan

2. Department of Thoracic Oncology National Hospital Organization Kyushu Cancer Center Fukuoka Japan

3. Division of Thoracic Oncology Shizuoka Cancer Center Shuntougun Japan

4. Department of Medical Oncology Kindai University Faculty of Medicine Osaka‐Sayama Japan

5. Department of Medical Oncology National Hospital Organization Yamaguchi Ube Medical Center Ube Japan

6. Department of Thoracic Oncology Kansai Medical University Osaka Japan

7. Department of Respiratory Medicine Kanagawa Cardiovascular and Respiratory Center Kanagawa Japan

8. Department of Thoracic Medical Oncology The Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan

9. Department of Respiratory Medicine Miyagi Cancer Center Natori Japan

10. Department of Pulmonary Medicine Sendai Kousei Hospital Miyagi Japan

11. Department of Thoracic Oncology National Cancer Center Hospital East Kashiwa Japan

12. Department of Respiratory Medicine and Medical Oncology National Hospital Organization Nagoya Medical Center Nagoya Japan

13. Research Institute for Diseases of the Chest Graduate School of Medical Sciences Kyushu University Fukuoka Japan

14. Internal Medicine III Wakayama Medical University Wakayama Japan

15. Department of Thoracic Oncology Saitama Cancer Center Saitama Japan

16. Department of Respiratory Medicine, Respiratory Center Totanomon Hospital Tokyo Japan

17. Division of Integrated Oncology Institute of Biomedical Research and Innovation Hospital Kobe Japan

18. Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan

19. Department of Thoracic Oncology Aichi Cancer Center Aichi Japan

20. Department of Respiratory Medicine and Medical Oncology Yokohama Municipal Citizen’s Hospital Yokohama Japan

21. Department of Thoracic Oncology National Hospital Organization Kinki‐Chuo Chest Medical Center Sakai Japan

22. Department of Surgery Tokyo Medical University Tokyo Japan

23. MSD K.K. Tokyo Japan

24. Merck & Co., Inc. Kenilworth NJ USA

25. Center for Innovative Clinical Medicine Okayama University Hospital Okayama Japan

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14647

Reference20 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Japan Lung Cancer Society.Guidelines for lung cancer clinical practice 2018 edition: Non‐small cell lung cancer;2018.https://www.haigan.gr.jp/guideline/2018/1/2/180102070100.html#j_7‐2_1. Accessed January 11 2019

3. First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review

4. National Comprehensive Cancer Network (NCCN).NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non‐small cell lung cancer version 5.2019;2019.www.nccn.org. Accessed June 12 2019

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Usefulness of Quantification and Serial Monitoring of Fine Crackles for Early Detection of Treatment-related Lung Injury: A Report of Two Cases;Internal Medicine;2024

2. PD-L1: expression regulation;Blood Science;2023-01-13

3. The Controversial Role of IL-33 in Lung Cancer;Frontiers in Immunology;2022-05-12

4. Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1;Thoracic Cancer;2022-04-30